SCHEMBL9944385

SCHEMBL9944385

Cc1cccnc1C(=O)OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.46
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
F2 P00734 1/20 0.40
PLAU P00749 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BRD4 O60885 1/20 0.40
KMT2A Q03164 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28241780 0.83 MAPT (0.50) ELANECA12CA1CA2CA7
SCHEMBL28423158 0.81 MAPT (0.46) ELANECA12CA1CA2CA7
SCHEMBL28430192 0.81 GRM4 (0.43) ELANECA12CA1CA2CA7
SCHEMBL28851020 0.80 L3MBTL1 (0.45) L3MBTL1MAPTALDH1A1NPSR1PLAU
SCHEMBL128711 0.80 L3MBTL1 (0.62) L3MBTL1ALDH1A1NPSR1SMN1; SMN2BRD4
SCHEMBL31347575 0.80 L3MBTL1 (0.62) L3MBTL1ALDH1A1NPSR1SMN1; SMN2BRD4
SCHEMBL4147133 0.80 KDM4E (0.61) ELANECA12CA1CA2CA7
SCHEMBL967834 0.79 ELANE (0.46) ELANECA12CA1CA2CA7
SCHEMBL4069169 0.79 MAPT (0.45) ELANECA12CA1CA2CA7
SCHEMBL5192649 0.79 TRIM24 (0.42) ELANECA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846291-B2 Resist composition, method of forming resist pattern, and new compound TOKYO OHKA KOGYO CO. LTD. (JP) 2014-09-30 US disclosed
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148955-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND C1R, SLC11A2, RER1 ELANE 889/4885CA12 1296/4885CA1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.